Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules


Por: Sadarangani M, Sell T, Iro MA, Snape MD, Voysey M, Finn A, Heath PT, Bona G, Esposito S, Diez-Domingo J, Prymula R, Odueyungbo A, Toneatto D, Pollard AJ and European MenB Vaccine Study Group
Publicada: 16 oct 2017
Categoría: Medicine (miscellaneous)
Resumen:
BACKGROUND: One schedule for the capsular group B meningococcal vaccine 4CMenB is 2 doses that are administered 2 months apart for children aged 12-23 months, with a booster dose 12-24 months later. Our objective was to provide data on persistence of human serum bactericidal antibody (hSBA) titres in children up to 4 years of age after initial doses at 12-24 months, and immunogenicity of a booster dose at 48 months of age compared with vaccine-naive children. METHODS: Children previously immunized, as part of a randomized controlled trial, with 2 doses of 4CMenB vaccine at 12-24 months of age received a booster at 4 years of age. Vaccine-naive age-matched toddlers received 2 doses of 4CMenB. Human serum bactericidal antibody titres against reference strains H44/76, 5/99, NZ98/254 and M10713 were evaluated before and after innoculation with 4CMenB vaccine in 4-year-old children. RESULTS: Of 332 children in the study, 123 had previously received 4CMenB and 209 were vaccine-naive controls. Before the booster, the proportions of participants (previously vaccinated groups compared with controls) with hSBA titres of 1:5 or more were as follows: 9%-11% v. 1% (H44/76), 84%-100% v. 4% (5/99), 0%-18% v. 0% (NZ98/254) and 59%-60% v. 60% (M10713). After 1 dose of 4CMenB in previously immunized children, the proportions of participants achieving hSBA titres of 1:5 or more were 100% (H44/76 and 5/99), 70%-100% (NZ98/254) and 90%-100% (M10713). INTERPRETATION: We found that waning of hSBA titres by 4 years of age occurred after 2 doses of 4CMenB vaccine administered at 12-24 months, and doses at 12-24 months have a priming effect on the immune system. A booster may be necessary to maintain hSBA titres of 1:5 or more among those children with increased disease risk. Trial registration: ClinicalTrials.gov, no. NCT01717638
Filiaciones:
Sadarangani M:
 Oxford Vaccine Group, Department of Paediatrics (Sadarangani, Sell, Iro, Snape, Voysey, Pollard), University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, UK

 Vaccine Evaluation Center (Sadarangani), BC Children's Hospital Research Institute, The University of British Columbia, Vancouver, BC

 Nuffield Department of Primary Care Health Sciences (Voysey), University of Oxford, Oxford, UK

 Bristol Children's Vaccine Centre (Finn), School of Clinical Sciences, University of Bristol, Bristol, UK

 St. George's Vaccine Institute (Heath), University of London, London, UK

 Azienda Ospedaliero-Universitaria Maggiore della Carita (Bona), Clinica Pediatrica, Novara, Italy

 Pediatric Highly Intensive Care Unit (Esposito), Universita degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

 Vaccine Research Area (Diez-Domingo), Fundación para el Fomento de la Investigación Sanitaria y Biomédica (FISABIO), Valencia, Spain

 Charles University Prague, School of Medicine, Department of Social Sciences (Prymula), Hradec Kralove, Czech Republic

 Novartis Vaccines and Diagnostics Inc. (Odueyungbo), Cambridge, Mass

 Hoffmann-La Roche Limited (Odueyungbo), Mississauga, Ont

 GSK (Toneatto), Siena, Italy
Sell T:
 Oxford Vaccine Group, Department of Paediatrics (Sadarangani, Sell, Iro, Snape, Voysey, Pollard), University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, UK

 Vaccine Evaluation Center (Sadarangani), BC Children's Hospital Research Institute, The University of British Columbia, Vancouver, BC

 Nuffield Department of Primary Care Health Sciences (Voysey), University of Oxford, Oxford, UK

 Bristol Children's Vaccine Centre (Finn), School of Clinical Sciences, University of Bristol, Bristol, UK

 St. George's Vaccine Institute (Heath), University of London, London, UK

 Azienda Ospedaliero-Universitaria Maggiore della Carita (Bona), Clinica Pediatrica, Novara, Italy

 Pediatric Highly Intensive Care Unit (Esposito), Universita degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

 Vaccine Research Area (Diez-Domingo), Fundación para el Fomento de la Investigación Sanitaria y Biomédica (FISABIO), Valencia, Spain

 Charles University Prague, School of Medicine, Department of Social Sciences (Prymula), Hradec Kralove, Czech Republic

 Novartis Vaccines and Diagnostics Inc. (Odueyungbo), Cambridge, Mass

 Hoffmann-La Roche Limited (Odueyungbo), Mississauga, Ont

 GSK (Toneatto), Siena, Italy
Iro MA:
 Oxford Vaccine Group, Department of Paediatrics (Sadarangani, Sell, Iro, Snape, Voysey, Pollard), University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, UK

 Vaccine Evaluation Center (Sadarangani), BC Children's Hospital Research Institute, The University of British Columbia, Vancouver, BC

 Nuffield Department of Primary Care Health Sciences (Voysey), University of Oxford, Oxford, UK

 Bristol Children's Vaccine Centre (Finn), School of Clinical Sciences, University of Bristol, Bristol, UK

 St. George's Vaccine Institute (Heath), University of London, London, UK

 Azienda Ospedaliero-Universitaria Maggiore della Carita (Bona), Clinica Pediatrica, Novara, Italy

 Pediatric Highly Intensive Care Unit (Esposito), Universita degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

 Vaccine Research Area (Diez-Domingo), Fundación para el Fomento de la Investigación Sanitaria y Biomédica (FISABIO), Valencia, Spain

 Charles University Prague, School of Medicine, Department of Social Sciences (Prymula), Hradec Kralove, Czech Republic

 Novartis Vaccines and Diagnostics Inc. (Odueyungbo), Cambridge, Mass

 Hoffmann-La Roche Limited (Odueyungbo), Mississauga, Ont

 GSK (Toneatto), Siena, Italy
Snape MD:
 Oxford Vaccine Group, Department of Paediatrics (Sadarangani, Sell, Iro, Snape, Voysey, Pollard), University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, UK

 Vaccine Evaluation Center (Sadarangani), BC Children's Hospital Research Institute, The University of British Columbia, Vancouver, BC

 Nuffield Department of Primary Care Health Sciences (Voysey), University of Oxford, Oxford, UK

 Bristol Children's Vaccine Centre (Finn), School of Clinical Sciences, University of Bristol, Bristol, UK

 St. George's Vaccine Institute (Heath), University of London, London, UK

 Azienda Ospedaliero-Universitaria Maggiore della Carita (Bona), Clinica Pediatrica, Novara, Italy

 Pediatric Highly Intensive Care Unit (Esposito), Universita degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

 Vaccine Research Area (Diez-Domingo), Fundación para el Fomento de la Investigación Sanitaria y Biomédica (FISABIO), Valencia, Spain

 Charles University Prague, School of Medicine, Department of Social Sciences (Prymula), Hradec Kralove, Czech Republic

 Novartis Vaccines and Diagnostics Inc. (Odueyungbo), Cambridge, Mass

 Hoffmann-La Roche Limited (Odueyungbo), Mississauga, Ont
Voysey M:
 Oxford Vaccine Group, Department of Paediatrics (Sadarangani, Sell, Iro, Snape, Voysey, Pollard), University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, UK

 Vaccine Evaluation Center (Sadarangani), BC Children's Hospital Research Institute, The University of British Columbia, Vancouver, BC

 Nuffield Department of Primary Care Health Sciences (Voysey), University of Oxford, Oxford, UK

 Bristol Children's Vaccine Centre (Finn), School of Clinical Sciences, University of Bristol, Bristol, UK

 St. George's Vaccine Institute (Heath), University of London, London, UK

 Azienda Ospedaliero-Universitaria Maggiore della Carita (Bona), Clinica Pediatrica, Novara, Italy

 Pediatric Highly Intensive Care Unit (Esposito), Universita degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

 Vaccine Research Area (Diez-Domingo), Fundación para el Fomento de la Investigación Sanitaria y Biomédica (FISABIO), Valencia, Spain

 Charles University Prague, School of Medicine, Department of Social Sciences (Prymula), Hradec Kralove, Czech Republic

 Novartis Vaccines and Diagnostics Inc. (Odueyungbo), Cambridge, Mass

 Hoffmann-La Roche Limited (Odueyungbo), Mississauga, Ont

 GSK (Toneatto), Siena, Italy
Finn A:
 Oxford Vaccine Group, Department of Paediatrics (Sadarangani, Sell, Iro, Snape, Voysey, Pollard), University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, UK

 Vaccine Evaluation Center (Sadarangani), BC Children's Hospital Research Institute, The University of British Columbia, Vancouver, BC

 Nuffield Department of Primary Care Health Sciences (Voysey), University of Oxford, Oxford, UK

 Bristol Children's Vaccine Centre (Finn), School of Clinical Sciences, University of Bristol, Bristol, UK

 St. George's Vaccine Institute (Heath), University of London, London, UK

 Azienda Ospedaliero-Universitaria Maggiore della Carita (Bona), Clinica Pediatrica, Novara, Italy

 Pediatric Highly Intensive Care Unit (Esposito), Universita degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

 Vaccine Research Area (Diez-Domingo), Fundación para el Fomento de la Investigación Sanitaria y Biomédica (FISABIO), Valencia, Spain

 Charles University Prague, School of Medicine, Department of Social Sciences (Prymula), Hradec Kralove, Czech Republic

 Novartis Vaccines and Diagnostics Inc. (Odueyungbo), Cambridge, Mass

 Hoffmann-La Roche Limited (Odueyungbo), Mississauga, Ont

 GSK (Toneatto), Siena, Italy
Heath PT:
 Oxford Vaccine Group, Department of Paediatrics (Sadarangani, Sell, Iro, Snape, Voysey, Pollard), University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, UK

 Vaccine Evaluation Center (Sadarangani), BC Children's Hospital Research Institute, The University of British Columbia, Vancouver, BC

 Nuffield Department of Primary Care Health Sciences (Voysey), University of Oxford, Oxford, UK

 Bristol Children's Vaccine Centre (Finn), School of Clinical Sciences, University of Bristol, Bristol, UK

 St. George's Vaccine Institute (Heath), University of London, London, UK

 Azienda Ospedaliero-Universitaria Maggiore della Carita (Bona), Clinica Pediatrica, Novara, Italy

 Pediatric Highly Intensive Care Unit (Esposito), Universita degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

 Vaccine Research Area (Diez-Domingo), Fundación para el Fomento de la Investigación Sanitaria y Biomédica (FISABIO), Valencia, Spain

 Charles University Prague, School of Medicine, Department of Social Sciences (Prymula), Hradec Kralove, Czech Republic

 Novartis Vaccines and Diagnostics Inc. (Odueyungbo), Cambridge, Mass

 Hoffmann-La Roche Limited (Odueyungbo), Mississauga, Ont

 GSK (Toneatto), Siena, Italy
Bona G:
 Oxford Vaccine Group, Department of Paediatrics (Sadarangani, Sell, Iro, Snape, Voysey, Pollard), University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, UK

 Vaccine Evaluation Center (Sadarangani), BC Children's Hospital Research Institute, The University of British Columbia, Vancouver, BC

 Nuffield Department of Primary Care Health Sciences (Voysey), University of Oxford, Oxford, UK

 Bristol Children's Vaccine Centre (Finn), School of Clinical Sciences, University of Bristol, Bristol, UK

 St. George's Vaccine Institute (Heath), University of London, London, UK

 Azienda Ospedaliero-Universitaria Maggiore della Carita (Bona), Clinica Pediatrica, Novara, Italy

 Pediatric Highly Intensive Care Unit (Esposito), Universita degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

 Vaccine Research Area (Diez-Domingo), Fundación para el Fomento de la Investigación Sanitaria y Biomédica (FISABIO), Valencia, Spain

 Charles University Prague, School of Medicine, Department of Social Sciences (Prymula), Hradec Kralove, Czech Republic

 Novartis Vaccines and Diagnostics Inc. (Odueyungbo), Cambridge, Mass

 Hoffmann-La Roche Limited (Odueyungbo), Mississauga, Ont

 GSK (Toneatto), Siena, Italy
Esposito S:
 Oxford Vaccine Group, Department of Paediatrics (Sadarangani, Sell, Iro, Snape, Voysey, Pollard), University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, UK

 Vaccine Evaluation Center (Sadarangani), BC Children's Hospital Research Institute, The University of British Columbia, Vancouver, BC

 Nuffield Department of Primary Care Health Sciences (Voysey), University of Oxford, Oxford, UK

 Bristol Children's Vaccine Centre (Finn), School of Clinical Sciences, University of Bristol, Bristol, UK

 St. George's Vaccine Institute (Heath), University of London, London, UK

 Azienda Ospedaliero-Universitaria Maggiore della Carita (Bona), Clinica Pediatrica, Novara, Italy

 Pediatric Highly Intensive Care Unit (Esposito), Universita degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

 Vaccine Research Area (Diez-Domingo), Fundación para el Fomento de la Investigación Sanitaria y Biomédica (FISABIO), Valencia, Spain

 Charles University Prague, School of Medicine, Department of Social Sciences (Prymula), Hradec Kralove, Czech Republic

 Novartis Vaccines and Diagnostics Inc. (Odueyungbo), Cambridge, Mass

 Hoffmann-La Roche Limited (Odueyungbo), Mississauga, Ont

 GSK (Toneatto), Siena, Italy
:
 Oxford Vaccine Group, Department of Paediatrics (Sadarangani, Sell, Iro, Snape, Voysey, Pollard), University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, UK

 Vaccine Evaluation Center (Sadarangani), BC Children's Hospital Research Institute, The University of British Columbia, Vancouver, BC

 Nuffield Department of Primary Care Health Sciences (Voysey), University of Oxford, Oxford, UK

 Bristol Children's Vaccine Centre (Finn), School of Clinical Sciences, University of Bristol, Bristol, UK

 St. George's Vaccine Institute (Heath), University of London, London, UK

 Azienda Ospedaliero-Universitaria Maggiore della Carita (Bona), Clinica Pediatrica, Novara, Italy

 Pediatric Highly Intensive Care Unit (Esposito), Universita degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

 Vaccine Research Area (Diez-Domingo), Fundación para el Fomento de la Investigación Sanitaria y Biomédica (FISABIO), Valencia, Spain

 Charles University Prague, School of Medicine, Department of Social Sciences (Prymula), Hradec Kralove, Czech Republic

 Novartis Vaccines and Diagnostics Inc. (Odueyungbo), Cambridge, Mass

 Hoffmann-La Roche Limited (Odueyungbo), Mississauga, Ont

 GSK (Toneatto), Siena, Italy
Prymula R:
 Oxford Vaccine Group, Department of Paediatrics (Sadarangani, Sell, Iro, Snape, Voysey, Pollard), University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, UK

 Vaccine Evaluation Center (Sadarangani), BC Children's Hospital Research Institute, The University of British Columbia, Vancouver, BC

 Nuffield Department of Primary Care Health Sciences (Voysey), University of Oxford, Oxford, UK

 Bristol Children's Vaccine Centre (Finn), School of Clinical Sciences, University of Bristol, Bristol, UK

 St. George's Vaccine Institute (Heath), University of London, London, UK

 Azienda Ospedaliero-Universitaria Maggiore della Carita (Bona), Clinica Pediatrica, Novara, Italy

 Pediatric Highly Intensive Care Unit (Esposito), Universita degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

 Vaccine Research Area (Diez-Domingo), Fundación para el Fomento de la Investigación Sanitaria y Biomédica (FISABIO), Valencia, Spain

 Charles University Prague, School of Medicine, Department of Social Sciences (Prymula), Hradec Kralove, Czech Republic

 Novartis Vaccines and Diagnostics Inc. (Odueyungbo), Cambridge, Mass

 Hoffmann-La Roche Limited (Odueyungbo), Mississauga, Ont

 GSK (Toneatto), Siena, Italy
Odueyungbo A:
 Oxford Vaccine Group, Department of Paediatrics (Sadarangani, Sell, Iro, Snape, Voysey, Pollard), University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, UK

 Vaccine Evaluation Center (Sadarangani), BC Children's Hospital Research Institute, The University of British Columbia, Vancouver, BC

 Nuffield Department of Primary Care Health Sciences (Voysey), University of Oxford, Oxford, UK

 Bristol Children's Vaccine Centre (Finn), School of Clinical Sciences, University of Bristol, Bristol, UK

 St. George's Vaccine Institute (Heath), University of London, London, UK

 Azienda Ospedaliero-Universitaria Maggiore della Carita (Bona), Clinica Pediatrica, Novara, Italy

 Pediatric Highly Intensive Care Unit (Esposito), Universita degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

 Vaccine Research Area (Diez-Domingo), Fundación para el Fomento de la Investigación Sanitaria y Biomédica (FISABIO), Valencia, Spain

 Charles University Prague, School of Medicine, Department of Social Sciences (Prymula), Hradec Kralove, Czech Republic

 Novartis Vaccines and Diagnostics Inc. (Odueyungbo), Cambridge, Mass

 Hoffmann-La Roche Limited (Odueyungbo), Mississauga, Ont

 GSK (Toneatto), Siena, Italy
Toneatto D:
 Oxford Vaccine Group, Department of Paediatrics (Sadarangani, Sell, Iro, Snape, Voysey, Pollard), University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, UK

 Vaccine Evaluation Center (Sadarangani), BC Children's Hospital Research Institute, The University of British Columbia, Vancouver, BC

 Nuffield Department of Primary Care Health Sciences (Voysey), University of Oxford, Oxford, UK

 Bristol Children's Vaccine Centre (Finn), School of Clinical Sciences, University of Bristol, Bristol, UK

 St. George's Vaccine Institute (Heath), University of London, London, UK

 Azienda Ospedaliero-Universitaria Maggiore della Carita (Bona), Clinica Pediatrica, Novara, Italy

 Pediatric Highly Intensive Care Unit (Esposito), Universita degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

 Vaccine Research Area (Diez-Domingo), Fundación para el Fomento de la Investigación Sanitaria y Biomédica (FISABIO), Valencia, Spain

 Charles University Prague, School of Medicine, Department of Social Sciences (Prymula), Hradec Kralove, Czech Republic

 Novartis Vaccines and Diagnostics Inc. (Odueyungbo), Cambridge, Mass

 Hoffmann-La Roche Limited (Odueyungbo), Mississauga, Ont

 GSK (Toneatto), Siena, Italy
Pollard AJ:
 Oxford Vaccine Group, Department of Paediatrics (Sadarangani, Sell, Iro, Snape, Voysey, Pollard), University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, UK

 Vaccine Evaluation Center (Sadarangani), BC Children's Hospital Research Institute, The University of British Columbia, Vancouver, BC

 Nuffield Department of Primary Care Health Sciences (Voysey), University of Oxford, Oxford, UK

 Bristol Children's Vaccine Centre (Finn), School of Clinical Sciences, University of Bristol, Bristol, UK

 St. George's Vaccine Institute (Heath), University of London, London, UK

 Azienda Ospedaliero-Universitaria Maggiore della Carita (Bona), Clinica Pediatrica, Novara, Italy

 Pediatric Highly Intensive Care Unit (Esposito), Universita degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

 Vaccine Research Area (Diez-Domingo), Fundación para el Fomento de la Investigación Sanitaria y Biomédica (FISABIO), Valencia, Spain

 Charles University Prague, School of Medicine, Department of Social Sciences (Prymula), Hradec Kralove, Czech Republic

 Novartis Vaccines and Diagnostics Inc. (Odueyungbo), Cambridge, Mass

 Hoffmann-La Roche Limited (Odueyungbo), Mississauga, Ont

 GSK (Toneatto), Siena, Italy
NIHR Oxford Biomed Res Ctr, Oxford, England.
ISSN: 08203946





CANADIAN MEDICAL ASSOCIATION JOURNAL
Editorial
CMA-CANADIAN MEDICAL ASSOC, Canada, Canada
Tipo de documento: Article
Volumen: 189 Número: 41
Páginas: 1276-1285
WOS Id: 000413572900003
ID de PubMed: 29038320
imagen Green Published, Green Submitted, gold, Green Accepted

MÉTRICAS